Gene · 4070
Papers3,230
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
241 to 260 of 3,230
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Expression of HER2, HER3, and TROP2 in primary tumors and brain metastases of breast cancer. | Breast Cancer | 2026 | 41824277 | PubTator, text mining | PubMed |
| TROP2 confers resistance to oxidative stress-induced cancer cell death through YAP/HMOX1 signaling. | J Transl Med | 2026 | 41814370 | PubTator, text mining | PubMed |
| Expression characteristics of clinically relevant antibody-drug conjugate targets in gestational trophoblastic neoplasia. | Hum Pathol | 2026 | 41812828 | PubTator, text mining | PubMed |
| Retrospective, Observational Analysis of Real-World Safety Outcomes in Patients With Locally Advanced/Metastatic Urothelial Cancer Treated With Sacituzumab Govitecan. | Clin Genitourin Cancer | 2026 | 41807147 | PubTator, text mining | PubMed |
| Multi-omic profiling defines three distinct molecular subtypes of urothelial carcinoma with implications for precision therapy. | Clin Transl Med | 2026 | 41804750 | PubTator, text mining | PubMed |
| Innovative Strategies of Nanocapsules for Maximizing Efficacy in Tumor Immunotherapy. | Int J Nanomedicine | 2026 | 41800437 | PubTator, text mining | PubMed |
| Advances in intratumoral immunotherapy from a neuro-immune-endocrine perspective for breast cancer treatment. | Front Oncol | 2026 | 41800053 | PubTator, text mining | PubMed |
| TROP-2 Is Not a Therapeutic Target in Melanoma: a Morphological Study. | Dermatol Ther (Heidelb) | 2026 | 41793593 | PubTator, text mining | PubMed |
| ELIOS: A Multicenter, Molecular Profiling Study of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer Treated with First-Line Osimertinib. | Cancer Discov | 2026 | 41790042 | PubTator, text mining | PubMed |
| Clinical applications of antibody-drug conjugates in advanced non-small cell lung cancer. | Front Immunol | 2026 | 41789080 | PubTator, text mining | PubMed |
| Primary Angiosarcomas of the Thyroid: New Insights Into the Genetic Background and Potentially Targetable Therapeutic Markers of an Ultrarare Disease. | Mod Pathol | 2026 | 41786211 | PubTator, text mining | PubMed |
| [68Ga]Ga-NOTA-T4 PET/CT imaging of TROP2 expression in patients with HER2-negative breast cancer. | Eur J Nucl Med Mol Imaging | 2026 | 41781717 | PubTator, text mining | PubMed |
| Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD. | Ann Oncol | 2026 | 41780641 | PubTator, text mining | PubMed |
| Companion Diagnostics in Clinical Therapy: Current Applications and Future Directions. | MedComm (2020) | 2026 | 41777248 | PubTator, text mining | PubMed |
| Antibody-drug conjugates in colorectal cancer: advances in targeted delivery and personalized oncology. | Front Bioeng Biotechnol | 2026 | 41768137 | PubTator, text mining | PubMed |
| A Critical Analysis of the Impact of Etoposide as a Topoisomerase II Inhibitor in Cervical Cancer Treatment: A Review. | Cancer Med | 2026 | 41766523 | PubTator, text mining | PubMed |
| Multiomic characterization of small cell lung cancer: Real-world insights into therapeutic opportunities. | Cancer | 2026 | 41761743 | PubTator, text mining | PubMed |
| Frontiers in Antibody-Drug Conjugates: Mechanisms, Design Innovations, and Clinical Applications in Targeted Cancer Therapy. | Pharmaceuticals (Basel) | 2026 | 41754865 | PubTator, text mining | PubMed |
| Large-Scale Plasma Proteomics and Genetic Integration Uncover Novel Biological Pathways in Male Pattern Baldness. | Int J Mol Sci | 2026 | 41752186 | PubTator, text mining | PubMed |
| Membrane-Anchored Serine Protease Inhibitors: Physiological Functions, Mechanisms, and Roles in Cancer. | Int J Mol Sci | 2026 | 41752136 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4070/papers?page=13